5 completed. 2 Phase 1, 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Angiofibroma: new trials by email Literature Review of Angiofibroma trials Research Report on Angiofibroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase III Trial of Topical Formulation of Sirolimus to Skin Lesions in Patients With Tuberous Sclerosis Complex (TSC) NPC-12G gel, Placebo gel - Tuberous Sclerosis, Angiofibroma | Phase 3 | Completed | Nobelpharma | 62 | 2015-12-01 | 2017-02-02 |
| Long-term Trial of Topical Sirolimus to Angiofibroma in Patient With Tuberous Sclerosis Complex NPC-12G gel - Tuberous Sclerosis, Angiofibroma | Phase 3 | Completed | Nobelpharma | 94 | 2015-12-01 | 2019-02-20 |
| Tuberous Sclerosis Complex: Facial Angiofibroma Skin Cream Rapamune - Facial Angiofibroma | Phase 1 | Completed | Le Bonheur Children's Hospital | 11 | 2013-10-01 | 2016-08-19 |
| Topical Rapamycin to Erase Angiofibromas in TSC Placebo, Rapamycin - Angiofibromas, Tuberous Sclerosis | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 179 | 2012-05-01 | 2020-10-26 |
| Topical Rapamycin Therapy to Alleviate Cutaneous Manifestations of Tuberous Sclerosis Complex (TSC) and Neurofibromatosis I (NF1) Skincerity, Skincerity plus sirolimus/rapamycin, Skinercity plus sirolimus/rapamycin - Tuberous Sclerosis, Neurofibromatoses | Phase 1 | Completed | The University of Texas Health Science Center, Houston | 52 | 2009-12-01 | 2012-02-27 |
Tuberous Sclerosis (5) · Plaque, Amyloid (2) · Neurofibroma (1) · Neurofibromatoses (1)
Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Genetic Diseases, Inborn (5) · Hamartoma (5) · Heredodegenerative Disorders, Nervous System (5) · Malformations of Cortical Development (5) · Malformations of Cortical Development, Group I (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms, Multiple Primary (5) · Neoplasms, Vascular Tissue (5) · Neoplastic Syndromes, Hereditary (5) · Nervous System Diseases (5) · Nervous System Malformations (5) · Neurocutaneous Syndromes (5)
Sirolimus (3)
Nobelpharma (2) · The University of Texas Health Science Center, Houston (2) · Le Bonheur Children's Hospital (1)
United States (3) · Japan (2) · Australia (1)
Hope Northrup, MD (2) · Mary Kay Koenig, MD (2) · James W Wheless, MD (1) · Mari Wataya-Kaneda, MD, PhD (1) · Mari Wataya-Kaneda,, MD, PhD (1)